NANEXA AB (PUBL) Inactive Instrument
Nanexa AB (publ) Share Price Nasdaq Stockholm
Equities
SE0007074166
Medical Equipment, Supplies & Distribution
| Sales 2024 * | 71.3M 6.67M 527M | Sales 2025 * | 69.5M 6.5M 514M | Capitalization | 125M 11.65M 921M |
|---|---|---|---|---|---|
| Net income 2024 * | 16M 1.5M 118M | Net income 2025 * | -4M -374K -29.56M | EV / Sales 2024 * | 0.83 x |
| Net cash position 2024 * | 65.5M 6.13M 484M | Net cash position 2025 * | 82M 7.67M 606M | EV / Sales 2025 * | 0.61 x |
| P/E ratio 2024 * |
23
x | P/E ratio 2025 * |
4.17
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nanexa AB (publ)
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Mårten Rooth
FOU | Founder | 47 | 31/12/06 |
Anders Johansson
FOU | Founder | 48 | 31/12/06 |
David Westberg
CEO | Chief Executive Officer | 64 | 31/03/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 01/06/20 | |
| Director/Board Member | 69 | 31/12/22 | |
| Corporate Officer/Principal | 62 | 31/12/14 |
Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.
Calendar
26/08/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +0.60% | 217M | |
| -60.48% | 83.48M |
